Potential Biological Warfare Agents
 

Disease

Incubation

Symptoms

Signs

Diagnostic tests

Transmission and Precautions

Treatment

(Adult dosage)

Prophylaxis

Inhaled Anthrax

2-6 days

Range: 2 days to 8 weeks

Flu-like symptoms

Respiratory distress

Widened mediastinum on chest X-ray (from adenopathy)

Atypical pneumonia

Flu-like illness followed by abrupt onset of respiratory failure

Gram stain (“boxcar” shape)

Gram positive bacilli in blood culture

ELISA for toxin antibodies to help confirm

Aerosol inhalation

No person-to-person transmission

Standard precautions

Mechanical ventilation

Antibiotic therapy

Ciprofloxacin 400 mg iv q 8-12 hr

Doxycycline 200 mg iv initial, then 100 mg iv q 8-12 hr

Penicillin 2 mil units iv q 2 hr

   -- possibly add gentamicin

Ciprofloxacin 500 mg po bid or doxycycline 100 mg po bid for ~ 8 weeks  (shorter with  anthrax vaccine)

FDA-approved vaccine: administer after exposure if available

Botulism

12-72 hours

Range:

2 hrs – 8 days

Difficulty swallowing or speaking (symmetrical cranial neuropathies)

Symmetric descending weakness

Respiratory dysfunction

No sensory dysfunction

No fever

Dilated or un-reactive pupils

Drooping eyelids (ptosis)

Double vision (diplopia)

Slurred speech (dysarthria)

Descending  flaccid paralysis

Intact mental state

Mouse bioassay in public health  laboratories (5 – 7 days to conduct)

ELISA for toxin

Aerosol inhalation

Food ingestion

No person-to-person transmission

Standard precautions

Mechanical ventilation

Parenteral nutrition

Trivalent botulinum antitoxin available from State Health Departments and CDC

Experimental vaccine has been used in laboratory workers

Plague

1-3 days by inhalation

Sudden onset of fever, chills, headache, myalgia

Pneumonic: cough, chest pain, hemoptysis

Bubonic : painful lymph nodes

Pneumonic:  Hemoptysis;

  radiographic pneumonia --

    patchy, cavities, confluent consolidation

Bubonic:   typically painful, enlarged lymph nodes in groin, axilla, and neck

Gram negative coccobacilli and bacilli in sputum, blood, CSF, or bubo aspirates (bipolar, closed “safety pin” shape on Wright, Wayson's stains)

ELISA, DFA, PCR

Person-to-person transmission  in pneumonic forms

Droplet precautions until patient treated for at least three days

Streptomycin 30 mg/kg/day in two divided doses x 10 days

Gentamicin 1-1.75 mg/kg iv/im q 8 hr

Tetracycline 2-4 g per day

Asymptomatic contacts; or potentially exposed

Doxycycline 100 mg po q 12 hr x 7 days

Ciprofloxacin 500 mg po

Tetracycline 250 mg po q 6 hr x 7 days

Vaccine production discontinued

Tularemia

“pneumonic”

2-5 days

Range:

1-21 days

Fever, cough, chest tightness, pleuritic pain

Hemoptysis rare

Community-acquired, atypical pneumonia

Radiographic: bilateral patchy pneumonia with hilar adenopathy (pleural effusions like TB)

Diffuse, varied skin rash

May be rapidly fatal

Gram negative bacilli in blood culture on  BYCE (Legionella) cysteine- or S-H-enhanced media

Serologic testing  to confirm: ELISA, microhemagglutination

DFA for sputum or local discharge

Inhalation of agents

No person-to-person transmission but laboratory personnel at risk

Standard precautions

Streptomycin 30 mg/kg/day IM divided bid for 10-14 days

Gentamicin 3-5 mg/kg/day iv in equal divided shoulders x 10-14 days

Ciprofloxacin possibly effective 400 mg iv q 12 hr (change to po after clinical improvement) x 10-14 days

Ciprofloxacin 500 mg po q 12 hr x 2 wks

Doxycycline 100 mg po q 12 hr x 2 wks

Tetracycline 250 mg po q 6 hr

Experimental live vaccine

Smallpox

12-14 days

Range:7-17 days

High fever and myalgia;

itching; abdominal pain; delirium

Rash on face, extremities, hands, feet; confused with chickenpox which has less uniform rash

Maculopapular then vesicular rash --  first on extremities (face, arms, palms, soles, oral mucosa)

Rash is synchronous on various segments of the body

Electron microscopy of pustule content

PCR

Public health  lab for confirmation

Person-to-person transmission

Airborne precautions

Negative pressure

Clothing  and surface decontamination

Supportive care

Vaccinate care givers

Vaccination (vaccine available from CDC)